Bavishi Chirag
Division of Cardiology, University of Missouri School of Medicine Columbia, MO.
US Cardiol. 2023 May 25;17:e05. doi: 10.15420/usc.2022.37. eCollection 2023.
Transcatheter left atrial appendage closure has emerged as a non-pharmacological alternative to long-term anticoagulation for stroke prevention in appropriately selected patients with AF. In this concise review, the Food and Drug Administration-approved and some other left atrial appendage closure devices that are under investigation are discussed. Currently, Watchman Flx and Amplatzer Amulet are the only two devices that have been approved for commercial use by the Food and Drug Administration. A brief overview of device designs, clinical data on efficacy and safety, major limitations of left atrial appendage closure devices, and perspectives on future direction are provided. The current generation of devices is effective; however, efforts should continue on innovations and refinement of device technology.
经导管左心耳封堵术已成为一种非药物替代疗法，用于在适当选择的房颤患者中预防中风的长期抗凝治疗。在这篇简要综述中，讨论了美国食品药品监督管理局（FDA）批准的以及其他一些正在研究中的左心耳封堵装置。目前，Watchman Flx和Amplatzer Amulet是仅有的两种已获FDA批准可用于商业用途的装置。本文提供了装置设计的简要概述、疗效和安全性的临床数据、左心耳封堵装置的主要局限性以及未来方向的展望。当前一代装置是有效的；然而，应继续努力进行装置技术的创新和改进。
